GHK-Cu and the collagen pathway

GHK is a tripeptide — glycyl-L-histidyl-L-lysine — naturally present in human plasma. It binds copper(II) with high affinity to form GHK-Cu, the form that shows up in most of the dermatology literature. Plasma levels of GHK fall sharply with age, from roughly 200 ng/mL in young adults to under 80 ng/mL by the seventh decade, which is part of why interest in topical replacement has persisted for forty years.

In cultured dermal fibroblasts, GHK-Cu has been shown to upregulate collagen type I and type III synthesis, increase production of glycosaminoglycans like decorin, and modulate metalloproteinases involved in extracellular matrix turnover. Pickart and colleagues, who have published on the molecule since the 1970s, have catalogued effects on more than 4,000 human genes — many of them associated with tissue remodeling, antioxidant defense, and wound repair.

These are mechanism-of-action results in cells, not clinical outcomes in skin. They establish a plausible biological pathway but do not, on their own, predict cosmetic effect.

Smaller controlled human studies — most in the 20- to 70-subject range — have reported improvements in skin density, elasticity, and the appearance of fine lines after 12 weeks of topical GHK-Cu use, compared with vehicle or placebo formulations. A frequently cited 2015 review by Pickart and Margolina summarizes the dermatology and wound-healing literature in detail.

The studies are not large, the formulations vary, and head-to-head comparisons with retinoids or vitamin C are scarce. The honest summary is that the mechanism is well characterized, the topical safety profile is favorable, and the cosmetic effect sizes are modest but consistent.

The copper ion is not incidental. Lysyl oxidase, the enzyme that crosslinks collagen and elastin fibers, is copper-dependent. By delivering bioavailable copper to the dermis bound to a stable carrier peptide, GHK-Cu plausibly supports the structural protein crosslinking that gives skin its mechanical resilience.